July 2 (Reuters) - Vyne Therapeutics Inc VYNE.O:
VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202
VYNE THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD FOR FEMALE PATIENTS ON 0.25 MG AND 0.5 MG DOSES
VYNE THERAPEUTICS INC - 12-WEEK TOXICOLOGY STUDY IN DOGS REQUIRED TO RESUME TRIAL IN MALES
VYNE THERAPEUTICS INC - TO STOP ENROLLING PATIENTS IN PHASE 1B PSORIASIS STUDY
VYNE THERAPEUTICS INC - UNBLINDS CLINICAL DATA FROM ENROLLED SUBJECTS IN STUDY
Source text: ID:nGNX4z5k55
Further company coverage: VYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.